Occurrence and clinical features of XXXX after chemoradiotherapy for @entity418 .

@entity1 @entity75 @entity5 @entity16 @entity957 @entity281 @entity418 @entity3
Brain @entity3 from @entity418 has been considered rare and survival following @entity418 with distant @entity3 is poor. The purpose of this report was to clarify cumulative incidence and risk factors for @entity75 after chemoradiotherapy for @entity418 , and to consider recommended treatments for @entity75 from @entity418 . We reviewed 391 @entity1 treated with chemoradiotherapy. Median age was 65 years. Clinical stages were I, II, III, and IV in 32, 47, 150, and 162 @entity1 , respectively. Brain imaging was performed usually when @entity1 revealed @entity16 . The 3-year cumulative incidence of @entity75 after chemoradiotherapy was 6.6%. There were 4 @entity1 with single @entity3 and 8 with multiple @entity3 . Initial clinical stages were II, III, and IV in 1, 2, and 9 @entity1 , respectively. Histology included @entity957 in 10 @entity1 and others in 2 @entity1 . Univariate analysis demonstrated M factor, distant lymph node relapse, and recurrent lung and liver @entity3 as significant risk factors of @entity75 (P < 0.05). Median survival time after diagnosis of @entity75 was 2.1 months. Brain @entity3 was not directly related to cause of mortality. The causes were extracranial @entity5 deterioration in 8 @entity1 and @entity281 in 4 @entity1 . Brain @entity3 may increase in the future with improving survival from @entity418 . However, considering the poor survival after diagnosis of @entity75 , short-term palliative therapy for @entity75 appears preferable to vigorous long-term therapy.
